Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


02.09.2019

1 Ann Surg
1 Ann Surg Oncol
2 Ann Thorac Surg
2 BMC Cancer
2 Cancer
1 Cancer Chemother Pharmacol
3 Cancer Sci
3 Clin Cancer Res
1 Clin Exp Metastasis
3 Clin Lung Cancer
2 Eur J Cancer
1 Hum Pathol
1 Int J Cancer
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
1 J Clin Oncol
7 J Thorac Oncol
27 Lung Cancer
1 PLoS Comput Biol
2 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg

  1. BROWN LM, Thibault DP, Kosinski AS, Cooke DT, et al
    Readmission after Lobectomy for Lung Cancer: Not All Complications Contribute Equally.
    Ann Surg. 2019 Aug 28. doi: 10.1097/SLA.0000000000003561.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. LIU L, Zhang Z
    ASO Author Reflections: The Dissection of Station 4L Lymph Node for Left-Sided Non-Small Cell Lung Cancer Should Receive More Attention.
    Ann Surg Oncol. 2019 Aug 28. pii: 10.1245/s10434-019-07764.
    PubMed     Text format    


    Ann Thorac Surg

  3. NOMORI H, Shiraishi A, O'uchi T, Honma K, et al
    Positron emission tomography in T3/T4 non-small cell lung cancer after induction chemoradiotherapy.
    Ann Thorac Surg. 2019 Aug 22. pii: S0003-4975(19)31210.
    PubMed     Text format     Abstract available

  4. SONOBE M, Yutaka Y, Nakajima D, Hamaji M, et al
    Salvage surgery after chemo- or chemoradiotherapy for initially unresectable lung carcinoma.
    Ann Thorac Surg. 2019 Aug 21. pii: S0003-4975(19)31207.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. BECK TN, Kudinov AE, Dulaimi E, Boumber Y, et al
    Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    BMC Cancer. 2019;19:379.
    PubMed     Text format     Abstract available

  6. ISLAM KM, Anggondowati T, Deviany PE, Ryan JE, et al
    Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.
    BMC Cancer. 2019;19:835.
    PubMed     Text format     Abstract available


    Cancer

  7. LIN JJ, Gainor JF
    Time to tackle the blood-brain barrier in HER2-mutant lung cancer.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32460.
    PubMed     Text format    

  8. HUO J, Hong YR, Turner K, Bian J, et al
    Utilization pattern and service settings of palliative care for patients with metastatic non-small-cell lung cancer.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32478.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  9. MOURI A, Kaira K, Yamaguchi O, Shiono A, et al
    Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
    Cancer Chemother Pharmacol. 2019 Aug 23. pii: 10.1007/s00280-019-03926.
    PubMed     Text format     Abstract available


    Cancer Sci

  10. ZHOU X, Shou J, Sheng J, Xu C, et al
    Molecular and clinical analysis of Chinese patients with ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2019 Aug 23. doi: 10.1111/cas.14177.
    PubMed     Text format     Abstract available

  11. YAMASUGE W, Yamamoto Y, Fujigaki H, Hoshi M, et al
    Ido2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma.
    Cancer Sci. 2019 Aug 23. doi: 10.1111/cas.14179.
    PubMed     Text format     Abstract available

  12. MENG MB, Wang HH, Zaorsky NG, Sun BS, et al
    Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
    Cancer Sci. 2019 Aug 28. doi: 10.1111/cas.14185.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  13. BENAYED R, Offin M, Mullaney K, Sukhadia P, et al
    High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
    Clin Cancer Res. 2019;25:4712-4722.
    PubMed     Text format     Abstract available

  14. JONES MR, Williamson LM, Topham JT, Lee MKC, et al
    NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
    Clin Cancer Res. 2019;25:4674-4681.
    PubMed     Text format     Abstract available

  15. JONNA S, Feldman RA, Swensen J, Gatalica Z, et al
    Detection of NRG1 Gene Fusions in Solid Tumors.
    Clin Cancer Res. 2019;25:4966-4972.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  16. ZHOU J, Zhang S, Xu Y, Ye W, et al
    Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma.
    Clin Exp Metastasis. 2019 Aug 28. pii: 10.1007/s10585-019-09988.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  17. NISHIO M, Sugawara S, Atagi S, Akamatsu H, et al
    Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
    Clin Lung Cancer. 2019 Jul 31. pii: S1525-7304(19)30209.
    PubMed     Text format     Abstract available

  18. MITCHELL KG, Farooqi A, Ludmir EB, Corsini EM, et al
    Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 Aug 1. pii: S1525-7304(19)30211.
    PubMed     Text format     Abstract available

  19. FUKIHARA J, Sakamoto K, Koyama J, Ito T, et al
    Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Clin Lung Cancer. 2019 Aug 1. pii: S1525-7304(19)30210.
    PubMed     Text format     Abstract available


    Eur J Cancer

  20. MAK DWS, Li S, Minchom A
    Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Eur J Cancer. 2019;119:132-150.
    PubMed     Text format     Abstract available

  21. YUAN P, Huang S, Bao FC, Cao JL, et al
    Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Eur J Cancer. 2019;120:10-19.
    PubMed     Text format     Abstract available


    Hum Pathol

  22. KRENCZ I, Sebestyen A, Papay J, Lou Y, et al
    Correlation between immunohistochemistry and RICTOR FISH amplification in small cell lung carcinoma.
    Hum Pathol. 2019 Aug 24. pii: S0046-8177(19)30157.
    PubMed     Text format     Abstract available


    Int J Cancer

  23. KANG J, Chang Y, Ahn J, Oh S, et al
    Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study.
    Int J Cancer. 2019 Aug 27. doi: 10.1002/ijc.32640.
    PubMed     Text format     Abstract available


    Int J Oncol

  24. SATO H, Soh J, Aoe K, Fujimoto N, et al
    Droplet digital PCR as a novel system for the detection of microRNA34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Int J Oncol. 2019;54:2139-2148.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  25. SINGH AK, Gomez-Suescun JA, Stephans KL, Bogart JA, et al
    One versus three fractions of stereotactic body radiation therapy for peripheral stage I-II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial.
    Int J Radiat Oncol Biol Phys. 2019 Aug 22. pii: S0360-3016(19)33653.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  26. SONG T, Jiang L, Zhuo Z, Luo J, et al
    Impacts of thoracoscopic surgery and high grade histologic subtypes on spread through air spaces in small stage I lung adenocarcinomas.
    J Cancer Res Clin Oncol. 2019;145:2375-2382.
    PubMed     Text format     Abstract available

  27. SUN S, Hu Z, Huang S, Ye X, et al
    REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
    J Cancer Res Clin Oncol. 2019;145:2273-2283.
    PubMed     Text format     Abstract available

  28. ITO M, Miyata Y, Hirano S, Kimura S, et al
    Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2019;145:2325-2333.
    PubMed     Text format     Abstract available


    J Clin Oncol

  29. SIO TT, Mohindra P, Yu NY, Ashman JB, et al
    The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non-Small-Cell Lung Cancer Continues.
    J Clin Oncol. 2019 Aug 29:JCO1901330. doi: 10.1200/JCO.19.01330.
    PubMed     Text format    


    J Thorac Oncol

  30. GILL RR, Tsao AS, Kindler HL, Richards WG, et al
    Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Me
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30695.
    PubMed     Text format     Abstract available

  31. SEN T, Della Corte CM, Milutinovic S, Cardnell RJ, et al
    Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30692.
    PubMed     Text format     Abstract available

  32. OHUE Y, Kurose K, Karasaki T, Isobe M, et al
    Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691.
    PubMed     Text format     Abstract available

  33. HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
    Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.
    J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665.
    PubMed     Text format     Abstract available

  34. FANG W, Huang Y, Gan J, Hong S, et al
    A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
    J Thorac Oncol. 2019;14:e201-e202.
    PubMed     Text format    

  35. ARENBERG D
    Micronodules Detected on Lung Cancer Screening CT Scans.
    J Thorac Oncol. 2019;14:1501-1503.
    PubMed     Text format    

  36. BUROTTO M, Aren O, Renner A, Samtani S, et al
    Lung Cancer in Chile.
    J Thorac Oncol. 2019;14:1504-1509.
    PubMed     Text format    


    Lung Cancer

  37. OU SI, Cui J, Schrock AB, Goldberg ME, et al
    Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-
    Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614.
    PubMed     Text format    

  38. HE Y, Jia K, Dziadziuszko R, Zhao S, et al
    Galectin-9 in non-small cell lung cancer.
    Lung Cancer. 2019;136:80-85.
    PubMed     Text format     Abstract available

  39. GRIESINGER F, Korol EE, Kayaniyil S, Varol N, et al
    Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Lung Cancer. 2019;135:196-204.
    PubMed     Text format     Abstract available

  40. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].
    Lung Cancer. 2019 Aug 24. pii: S0169-5002(19)30617.
    PubMed     Text format    

  41. MORGENSZTERN D, Karaseva N, Felip E, Delgado I, et al
    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
    Lung Cancer. 2019;136:74-79.
    PubMed     Text format     Abstract available

  42. ALCARAZ J, Carrasco JL, Millares L, Luis IC, et al
    Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.
    Lung Cancer. 2019;135:151-160.
    PubMed     Text format     Abstract available

  43. FRASER I, Lefresne S, Regan J, Berthelet E, et al
    Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis.
    Lung Cancer. 2019;135:97-103.
    PubMed     Text format     Abstract available

  44. HOJBJERG JA, Ebert EBF, Clement MS, Winther-Larsen A, et al
    Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
    Lung Cancer. 2019;135:92-96.
    PubMed     Text format     Abstract available

  45. VILLARUZ LC, Cobo M, Syrigos K, Mavroudis D, et al
    A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Lung Cancer. 2019;136:52-56.
    PubMed     Text format     Abstract available

  46. YOKOYAMA T, Yoshioka H, Fujimoto D, Demura Y, et al
    A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Lung Cancer. 2019;135:175-180.
    PubMed     Text format     Abstract available

  47. HEINEMAN DJ, Hoeijmakers F, Beck N, Dickhoff C, et al
    Impact of health care organization on surgical lung cancer care.
    Lung Cancer. 2019;135:181-187.
    PubMed     Text format     Abstract available

  48. NOSAKI K, Saka H, Hosomi Y, Baas P, et al
    Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Lung Cancer. 2019;135:188-195.
    PubMed     Text format     Abstract available

  49. CADHAM CJ, Jayasekera JC, Advani SM, Fallon SJ, et al
    Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.
    Lung Cancer. 2019;135:205-216.
    PubMed     Text format     Abstract available

  50. MESSARITAKIS I, Nikolaou M, Koinis F, Politaki E, et al
    Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Lung Cancer. 2019;135:33-39.
    PubMed     Text format     Abstract available

  51. GUO J, Wang X, Wang Y, Wang L, et al
    A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
    Lung Cancer. 2019;135:47-55.
    PubMed     Text format     Abstract available

  52. KIM DW, Lee DH, Han JY, Lee J, et al
    Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Lung Cancer. 2019;135:66-72.
    PubMed     Text format     Abstract available

  53. HOPKINS RJ, Ko J, Gamble GD, Young RP, et al
    Airflow limitation and survival after surgery for non-small cell lung cancer: Results from a systematic review and lung cancer screening trial (NLST-ACRIN sub-study).
    Lung Cancer. 2019;135:80-87.
    PubMed     Text format     Abstract available

  54. ISLA D, De Las Penas R, Insa A, Marse R, et al
    Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
    Lung Cancer. 2019;135:161-168.
    PubMed     Text format     Abstract available

  55. BODOR JN, Feliciano JL, Edelman MJ
    Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation.
    Lung Cancer. 2019;135:16-20.
    PubMed     Text format     Abstract available

  56. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
    Lung Cancer. 2019 Aug 21. pii: S0169-5002(19)30618.
    PubMed     Text format    

  57. RAJADURAI P, Cheah PL, How SH, Liam CK, et al
    Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
    Lung Cancer. 2019;136:65-73.
    PubMed     Text format     Abstract available

  58. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
    Lung Cancer. 2019;135:1-9.
    PubMed     Text format     Abstract available

  59. NOOR ZS, Goldman JW, Lawler WE, Telivala B, et al
    Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;135:104-109.
    PubMed     Text format     Abstract available

  60. RUDNICKA J, Kowalkowski T, Buszewski B
    Searching for selected VOCs in human breath samples as potential markers of lung cancer.
    Lung Cancer. 2019;135:123-129.
    PubMed     Text format     Abstract available

  61. ZHANG L, Pu D, Liu D, Wang Y, et al
    Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
    Lung Cancer. 2019;135:130-137.
    PubMed     Text format     Abstract available

  62. UDAGAWA H, Akamatsu H, Tanaka K, Takeda M, et al
    Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    Lung Cancer. 2019;135:145-150.
    PubMed     Text format     Abstract available

  63. CAPIZZI E, Dall'Olio FG, Gruppioni E, Sperandi F, et al
    Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Lung Cancer. 2019;135:88-91.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  64. CRAIG M, Kaveh K, Woosley A, Brown AS, et al
    Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer.
    PLoS Comput Biol. 2019;15:e1007278.
    PubMed     Text format     Abstract available


    Thorax

  65. BRIMS F, Gunatilake S, Lawrie I, Marshall L, et al
    Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.
    Thorax. 2019;74:354-361.
    PubMed     Text format     Abstract available

  66. MARTINEZ-TERROBA E, Behrens C, Agorreta J, Monso E, et al
    5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.
    Thorax. 2019;74:371-379.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: